A new independent 590 page research with title ‘Hypertension – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis and important players/vendors such as Vivus, Suda, Relypsa etc. With n-number of tables and figures examining the Hypertension, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/852546-hypertension-pipeline-review-1
The latest Pharmaceutical and Healthcare disease pipeline guide Hypertension – Pipeline Review, H2 2017, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don’t occur until high blood pressure has reached a severe.
The Pharmaceutical and Healthcare latest pipeline guide Hypertension – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 40, 33, 31, 1, 87, 13 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 10 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=852546
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
A1M Pharma AB, Acceleron Pharma Inc, Ache Laboratorios Farmaceuticos SA, Actelion Pharmaceuticals Ltd, Aerogen Ltd, AnGes MG Inc, Arena Pharmaceuticals Inc, Ascendis Pharma A/S, Asklepion Pharmaceuticals LLC, AVEO Pharmaceuticals Inc, Bayer AG, Bial – Portela & Ca SA, Biogen Inc, Biolab Farmaceutica Ltda, BioRestorative Therapies Inc, Boryung Pharmaceutical Co Ltd, Bristol-Myers Squibb Co, Camurus AB, Capricor Therapeutics Inc, Celsion Corp, Celtaxsys Inc, Cereno Scientific AB, Chiesi Farmaceutici SpA, Chong Kun Dang Pharmaceutical Corp, Chugai Pharmaceutical Co Ltd, CJ HealthCare Corp, Complexa Inc, Corion Biotech Srl, Cumberland Pharmaceuticals Inc, D. Western Therapeutics Institute Inc, Daewon Pharm Co Ltd, Daewoong Co Ltd, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, DiaMedica Therapeutics Inc, Egalet Corp, Eli Lilly and Co, Esperion Therapeutics Inc, Galectin Therapeutics Inc, Gemphire Therapeutics Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, H. Lundbeck AS, HanAll Biopharma Co Ltd, Hanmi Pharmaceuticals Co Ltd, HitGen LTD, Idorsia Ltd, Ildong Pharmaceutical Co Ltd, Innopharmax Inc, Insmed Inc, Insys Therapeutics Inc, Ionis Pharmaceuticals Inc, Ironwood Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Johnson & Johnson, JW Pharmaceutical Corp, Leading BioSciences Inc, Lee’s Pharmaceutical Holdings Ltd, Les Laboratoires Servier SAS, LinXis BV, Liquidia Technologies Inc, Lotus Pharmaceutical Co Ltd, MannKind Corp, Marina Biotech Inc, Merck & Co Inc, Mezzion Pharma Co Ltd, Mitsubishi Tanabe Pharma Corp, N4 Pharma Plc, Nanoform Cardiovascular Therapeutics Ltd, Neurim Pharmaceuticals Ltd, Nippon Kayaku Co Ltd, Nippon Shinyaku Co Ltd, Nissan Chemical Industries Ltd, Northern Therapeutics Inc, Novartis AG, Omeros Corp, Peloton Therapeutics Inc, Pfizer Inc, PhaseBio Pharmaceuticals Inc, Pluristem Therapeutics Inc, Pulmokine Inc, Quantum Genomics SA, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, Relypsa Inc, Renova Therapeutics Inc, Respira Therapeutics Inc, Reviva Pharmaceuticals Inc, rEVO Biologics Inc, Rottapharm Biotech Srl, Sanofi, Sarfez Pharmaceuticals Inc, Savara Inc, Serodus ASA, Shanghai Pharmaceutical Co Ltd, SteadyMed Therapeutics Inc, Suda Ltd, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, Takeda Pharmaceutical Co Ltd, Target Medicals LLC, The Medicines Company, Theravance Biopharma Inc, Toray Industries Inc, Torrent Pharmaceuticals Ltd, United Therapeutics Corp, Vascular BioSciences, Vectura Group Plc, VG Life Sciences Inc, Vicore Pharma AB, Vivus Inc, XORTX Pharma Corp, XuanZhu Pharma Co Ltd, Yuhan Corp
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/852546-hypertension-pipeline-review-1
Hypertension – Overview 8
Hypertension – Therapeutics Development 9
Hypertension – Therapeutics Assessment 37
Hypertension – Companies Involved in Therapeutics Development 55
Hypertension – Drug Profiles 108
Hypertension – Dormant Projects 538
Hypertension – Discontinued Products 553
Hypertension – Product Development Milestones 555
Appendix 565List of Tables
Number of Products under Development for Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/852546-hypertension-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218